Home

Intelligence

Services

Subscriptions

News

About Us

Sign In

 

Document Preview

Press Release

 

Click "Add to Cart" button to purchase document. 
Documents are emailed immediately after purchase. 
You can also browse documents by
title, category, or company... or click here for help finding documents.

 

Title:

Press Release

Entities:

Genaera Corp.; University of California, Los Angeles

Date:

2003

Size:

7KB total

Price:

$37

ID:

#283385

 

 

► Miscellany ► News ► Press Releases ► Misc. Press Releases
► Miscellany ► Universities
► Biotech & Drugs ► Biological Products

 

 

Start of Preview


 

[GENAERA LOGO]

 

FOR IMMEDIATE RELEASE

 

Contact:

 

Genaera Corporation   The Trout Group/BMC Communications

Jennifer Bilotti

 

Jonathan Fassberg ext. 16 (investor inquiries)

(610) 941-4020

 

Brad Miles ext. 17 (media inquiries)

www.genaera.com

 

(212) 477-9007

 

Genaera Announces Presentation on Preclinical Squalamine Research

-VEGF Blockade Associated with Anti-Tumor Effects-

 

Plymouth Meeting, PA, November 4, 2003 /PRNewswire/Genaera Corporation (NASDAQ: GENR) today announced that Richard J. Pietras, PhD, MD, Associate Professor of Medicine at the University of California, Los Angeles (UCLA) Medical Center and Jonsson Comprehensive Cancer Center will present today preclinical research on squalamine at the XVII FIGO World Congress of Gynecology and Obstetrics in Santiago, Chile. The presentation is entitled Squalamine Blocks Tumor Associated Angiogenesis and Growth of Ovarian Cancer.

 

The presentation highlights that the anti-angiogenic effects of squalamine correlated well with squalamine induced blockade of the rapid vascular endothelial growth factor (VEGF) stimulated phosphorylation of p42/p44 MAP kinase in endothelial cells, an early cell response to activate proliferation. Squalamine also reduced VEGF induced phophorylation of focal adhesion kinase and stress activated protein kinase-2/p38, blocking in turn assembly of F-actin stress fibers in endothelial cells. These effects follow primary interaction of squalamine with caveolar domains at surface membranes of endothelial cells, sites for the concentration of vital signaling complexes to regulate the angiogenic process. The presentation concludes that the potent anti-tumor efficacy of squalamine is due to coordinated disruption of tumor associated angiogenesis.


 

End of Preview

 

Home        Intelligence        Services        Subscriptions        News        About Us

Contact Us       Terms of Use       Resend Documents       Shopping Cart

Copyright © 2008 The Consus Group LLC